Martínez De La Casa Fernández-Borrella, José MaríaCastillo, AGarcía Feijoo, JuliánMéndez Hernández, Carmen DoraFernández Vidal, Ana MaríaGarcía Sánchez, Julián2024-08-052024-08-052004-06Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, Mendez-Hernandez C, Fernandez-Vidal A, Garcia-Sanchez J. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of efficacy and safety. Curr Med Res Opin. 2004 Sep;20(9):1333-9. doi: 10.1185/030079904125004529. PMID: 15383180.10.1185/030079904125004529https://hdl.handle.net/20.500.14352/107369Purpose: To compare the efficacy and safety of the concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily with those of a fixed combination of latanoprost 0.005%/timolol 0.5% once daily. Research, design and methods: Forty-four patients with primary open-angle glaucoma or ocular hypertension with elevated IOP insufficiently responsive to monotherapy were randomly assigned to one of the two treatment groups: concomitant administration of travoprost 0.004% once daily and brinzolamide 0.1% twice daily (TB group: 22 patients) or latanoprost 0.005% plus timolol 0.5% once daily (LT group: 22 patients). Visits were undertaken at screening (current ocular hypotensive therapy was discontinued), baseline (randomization), and after 2 weeks, 1 month, 2 months and 3 months of therapy. Main outcome measures: IOP was determined at 9 a.m., 12 p.m. and 4 p.m. at each study visit, and diurnal IOP was calculated as the mean of these recordings. Adverse events were recorded at each visit. Results: IOP at the baseline visit was similar in both groups. Overall mean IOP was significantly lower in the TB as compared to the LT group after 1 month, 2 month and 3 month follow-up; only 9 a.m. measurements were significantly different, reaching a maximum difference (16.9 ± 0.9 mmHg vs 18.4 ± 1.8 mmHg, p < 0.001) at the 3 month check. The percentage of respondent (IOP decrease ≥ 30%) was higher in the TB group. Both treatments were well tolerated and there were no cases of withdrawal from treatment. Conclusions: Travoprost 0.004% and brinzolamide 0.1% concomitant therapy showed a greater efficacy than the fixed latanoprost 0.005%/timolol 0.5% combination in terms of absolute IOP decreases. Travoprost/brinzolamide therapy also offered the advantages of a greater percentage of responders.engjournal articlehttps://doi.org/10.1185/030079904125004529https://www.tandfonline.com/doi/abs/10.1185/030079904125004529restricted access617.7BrinzolamideFixed combinationGlaucomaLatanoprostTimololTravoprostOftalmología3201.09 Oftalmología